Modulation of ICAM-1 expression by α-MSH in human melanoma cells and melanocytes
Article first published online: 6 DEC 1998
Copyright © 1998 Wiley-Liss, Inc.
Journal of Cellular Physiology
Volume 175, Issue 3, pages 276–282, June 1998
How to Cite
Morandini, R., Boeynaems, J. M., Hedley, S. J., MacNeil, S. and Ghanem, G. (1998), Modulation of ICAM-1 expression by α-MSH in human melanoma cells and melanocytes. J. Cell. Physiol., 175: 276–282. doi: 10.1002/(SICI)1097-4652(199806)175:3<276::AID-JCP5>3.0.CO;2-L
- Issue published online: 6 DEC 1998
- Article first published online: 6 DEC 1998
- Manuscript Accepted: 6 OCT 1997
- Manuscript Received: 28 JUL 1997
α-MSH, a proopiomelanocortin (POMC)-derived peptide, is known to be produced in the pituitary, the skin, and melanoma tumors and to possess many biological effects, mainly on melanocyte pigmentation and growth. Moreover, the melanocyte expresses adhesion molecules, including ICAM-1. The latter has been reported to play a role in melanoma spread and associated metastatic process. We conducted a study in order to evaluate the possible effect of MSH on ICAM-1 expression in human cultured malignant and normal melanocytes. Our data show that α-MSH inhibits ICAM-1 expression stimulated by TNF in a concentration-dependent manner, both at the protein and gene expression level. Ninety percent inhibition was obtained with 10 nM MSH, while 50% inhibition was achieved with 1 nM. Endogenous cAMP elevation with forskolin as well as an exogenous cAMP stable analogue (Sp-cAMPS) produced the same inhibitory effect. A screening of malignant melanocytes showed that inhibition of ICAM-1 expression could be achieved only in those cells expressing detectable MSH receptors and seemed to correlate with the number of binding sites. In conclusion, our data strongly suggest α-MSH as a potent inhibitor of ICAM-1 expression in malignant melanocytes acting through MSH receptor stimulation and subsequent cAMP increase. J. Cell. Physiol. 175:276–282, 1998. © 1998 Wiley-Liss, Inc.